Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina's (ILMN) Complete Long Read Prep combines Illumina sequencing by synthesis chemistry with DRAGEN secondary analysis to provide WGS with more accuracy.

Illumina (ILMN) Unveils Complete Long Reads Technology

Carl Icahn wants three board seats at Illumina after it overpaid for Grail and took on too much regulatory risk. The $3.9 billion impairment charge Illumina took in the fourth quarter makes clear just how badly overpriced the deal was.

Icahn Reacts Audaciously To Illumina's Audacity

Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their ‘Buy' rating and $300 price target for Illumina Inc (NASDAQ:ILMN) after activist investor Carl Icahn said he is preparing a proxy fight at the gene sequencing company after its acquisition of Grail Inc wiped $50 billion of value from its market capitalization. In an open letter to shareholders published Monday, and first reported by the Wall Street Journal, Icahn announced his intention to nominate three directors to Illumina's board at its upcoming annual shareholders' meeting to weigh in on the decision to oppose a European Commission (EC) order to unwind the August 2021 takeover of Grail, a cancer-detection test maker.

Illumina retains ‘Buy' rating from Canaccord as activist investor Carl Icahn prepares for face-off

Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples SAN DIEGO , March 14, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now available to order. The high-performance, long-read, human whole-genome sequencing (WGS) assay – Illumina Complete Long Read Prep, Human – is compatible with Illumina NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 Sequencing Systems.

Illumina launches its first product enabling long- and short-read sequencing on one instrument

Sunny Isles Beach, Florida, March 13, 2023 — Today, Carl C. Icahn released the following open letter to the shareholders of Illumina, Inc. ( ILMN , Financial).

Carl Icahn Pens Open Letter to Illumina Shareholders

Illumina Inc. ILMN said Monday it received notice from Icahn Partners that the organization plans to nominate three candidates to to the board over concerns about the company's $7.1 billion acquisition of Grail. Jesse Lynn and Andrew Teno are current Icahn employees and Vincent Intrieri is a former Icahn employee.

Illumina: It's not in the ‘best interests' of shareholders to support Carl Icahn's nominees to the board

Illumina Inc (NASDAQ:ILMN) stock rallied more than 20% following reports in the Wall Street Journal that activist investor Carl Icahn is preparing a proxy fight at the gene sequencing company after its acquisition of Grail Inc wiped $50 billion of value from its market capitalization.  In an open letter to shareholders Monday, Icahn said: “This value destruction is a direct result of a series of ill-advised (and frankly inexplicable) actions taken by the board of directors of our company in connection with the acquisition of GRAIL, Inc. To paraphrase William Shakespeare's Hamlet, something is rotten in the state of Illumina.

'Something is rotten in the state of Illumina,' says activist investor Carl Icahn as he takes aim over Grail pursuit

SAN DIEGO , March 13, 2023 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN), a global leader in DNA sequencing and array-based technologies, confirmed today that it has received notice from Icahn Partners LP and certain of its affiliates of their intention to nominate three candidates—two current Icahn employees, Jesse Lynn and Andrew Teno, and one former Icahn employee, Vincent Intrieri—for election to the Board of Directors at Illumina's 2023 Annual Meeting of Shareholders. Illumina regularly engages with shareholders on its business, financial performance and corporate governance, and welcomes constructive engagement with the goal of increasing shareholder value.

Illumina Responds to Icahn Partners' Nomination of Directors

Activist investor Carl Icahn could press Illumina to divest its controversial Grail asset, analysts said Monday as ILMN stock surged. The post Illumina Surges As Activist Carl Icahn Reportedly Steps In Over Grail appeared first on Investor's Business Daily.

Illumina Surges As Activist Carl Icahn Reportedly Steps In Over Grail

Illumina (NASDAQ: ILMN ) stock is a hot topic among traders on Monday as reports claim Carl Icahn is gearing up for a proxy fight. According to a report from The Wall Street Journal, Icahn has issues with recent moves made by Illumina.

ILMN Stock Alert: What to Know as Carl Icahn Prepares for Proxy Fight With Illumina

Shares of Illumina Inc. ILMN, -4.24% were up about 8% in premarket trading on Monday after the Wall Street Journal reported Sunday that Carl Icahn is planning a proxy fight. The billionaire activist reportedly believes that the company's $7.1 billion acquisition of cancer-test maker Grail cost shareholders $50 billion.

WSJ: Carl Icahn says Grail deal cost Illumina shareholders $50 billion

Carl Icahn plans to nominate three people to Illumina's board, according to The Wall Street Journal.

Carl Icahn Is Taking Aim at Illumina

Activist investor Carl Icahn is preparing a proxy fight at Illumina Inc , arguing that the life science maker's acquisition of Grail Inc cost its shareholders roughly $50 billion, the Wall Street Journal reported on Sunday.

Carl Icahn prepares for proxy fight at Illumina - WSJ

The billionaire activist seeks three seats on biotech's board.

Icahn Prepares for Proxy Fight at Illumina

Bentley Systems

Avid Bioservices

Lantronix

Correctly spotting overpriced stocks and shunning them at the right time may avoid portfolio bleeding. ILMN, LTRX, BSY and CDMO are a few such toxic stocks.

Steer Clear Of These 4 Toxic Stocks to Avoid Losses

Illumina, Inc. (NASDAQ:ILMN ) 43rd Annual TD Cowen Health Care Conference March 7, 2023 9:50 AM ET Company Participants Joydeep Goswami - Chief Financial Officer & Chief Executive Officer Salli Schwartz - Investor Relations Conference Call Participants Dan Brennan - Cowen and Company Dan Brennan Greetings, Day two of TD Cowen Healthcare Conference. I'm Dan Brennan.

Illumina, Inc. (ILMN) Presents at 43rd Annual TD Cowen Health Care Conference (Transcript)

Myriad Genetics

Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry SAN DIEGO , March 2, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of a strategic partnership to broaden access to and availability of oncology homologous recombination deficiency (HRD) testing in the United States. Under the agreement, Illumina TruSight™ Oncology 500 HRD (TSO 500 HRD), a research-use-only test, is now available in the US.

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

Manulife Financial

Carrier previously became the first life insurer to offer access to the Galleri test through a pilot in 2022 TSX/NYSE/PSE: MFC SEHK: 945 BOSTON , Feb. 23, 2023 /PRNewswire/ -- Today, John Hancock , a unit of Manulife (NYSE: MFC), announced it will expand access to GRAIL's Galleri® multi-cancer early detection test to eligible life insurance customers participating in the John Hancock Vitality PLUS program, a significant milestone in John Hancock's ongoing efforts to help customers live longer, healthier, better lives. The expanded access comes after John Hancock became the first life insurance carrier to make the breakthrough screening technology available to a pilot group of customers in September 2022.

John Hancock expands access to Galleri®, GRAIL's breakthrough cancer screening technology

As sequencing costs fall, applications widen across research, medical care.

Startups Take On Illumina in Race for Cheaper DNA Sequencing

Booking Hlds

Fortinet

General Motors

MGM Resorts

ServiceNow

PayPal

When looking for stocks to buy and hold for the next 20 years, it's essential to find ones with economic moat. After all, when it comes to picking stocks, they should strong competitive advantages that are in durable sectors.

7 Stocks to Buy and Hold for the Next 20 Years

New data on NovaSeq X Plus and workflow insights on Illumina Complete Long Reads unveiled at AGBT HOLLYWOOD, Fla. , Feb. 8, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first NovaSeq X Plus system was recently delivered to the Broad Institute.

Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute

Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.

Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Illumina (ILMN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Illumina, Inc. (NASDAQ:ILMN ) Q4 2022 Earnings Conference Call February 7, 2023 5:00 PM ET Company Participants Sallilyn Schwartz - VP, IR Joydeep Goswami - CFO, Chief Strategy & Corporate Development Officer Francis deSouza - CEO & Director Conference Call Participants Puneet Souda - SVB Securities Daniel Arias - Stifel, Nicolaus & Company Daniel Brennan - Cowen and Company Vijay Kumar - Evercore ISI Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank David Westenberg - Piper Sandler & Co. Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2022 Illumina Earnings Conference Call. [Operator Instructions].

Illumina, Inc. (ILMN) Q4 2022 Earnings Call Transcript

Illumina (ILMN) delivered earnings and revenue surprises of -26.32% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Illumina Stock (ILMN)